Key Highlights
- Katie Price confirms son Harvey, 24, has been on Mounjaro (tirzepatide) for nearly a month after medical team approval despite complex medication regimen for Prader-Willi syndrome, autism, and sight impairment.
- Harvey weighs just under 30 stone (approx. 190 kg/420 lbs) with BMI double the obesity threshold; Price reveals doctors warn he is at high risk of heart attack and struggles with breathlessness and mobility.
- In latest podcast update, Price reports Harvey’s appetite has increased over the past 10 days, prompting a planned dosage increase at his upcoming clinic visit where he will be weighed.
Katie Price Shares Monthly Update on Harvey’s Mounjaro Treatment Amid Ongoing Health Concerns
Former glamour model and mother of five Katie Price has provided a candid update on her eldest son Harvey Price’s weight management journey, approximately one month after the 24-year-old began treatment with Mounjaro, the brand name for tirzepatide, a GLP-1 and GIP receptor agonist used for weight loss and type 2 diabetes. The update, delivered on her podcast The Katie Price Show, follows her previous revelation that Harvey’s weight had reached just under 30 stone (approximately 190 kilograms or 420 pounds), placing his body mass index at double the clinical threshold for obesity.
Complex Medical Background Necessitated Multi-Disciplinary Approval
Harvey lives with a rare genetic condition, Prader-Willi syndrome, which is characterized by chronic insatiable hunger, intellectual disability, and hormonal deficiencies, alongside autism and significant sight impairment. These co-morbidities, combined with his existing medication regimen, meant that initiating Mounjaro required extensive sign-off from his medical team. Price described the process on the Andrew Gold podcast: “I’ve tried going private with him to start him on Mounjaro, but because of his medical… it’s easy for me to just give it but because of his other medication, you have to have all the team tick it off.” Her sister Sophie Price previously noted the medication would “really help him” as he had been “struggling at the minute.”
Health Risks Drive Decision, Not Aesthetics
Price has been unequivocal that the decision to pursue pharmacologic intervention is motivated solely by Harvey’s deteriorating physical health and quality of life. She detailed the daily realities: “It’s getting to a point now, where he doesn’t want to walk anywhere, he gets out of breath and sweats and they have said he is at high risk of having a heart attack. I bathe him twice a day and it breaks my heart seeing him get in and out of the bath because he’s so big and heavy.” Summarizing her stance, she stated: “This isn’t for looks, it’s for a better quality of life for him.” Price also disclosed her own fear: “What I worry about is Harvey having a heart attack, his obesity. He weighs just under 30 stone.”
Early Treatment Response Shows Increased Appetite, Prompting Dosage Adjustment
In her most recent podcast episode, Price reported a notable development in Harvey’s response to the medication. “Harvey starts his next Mounjaro tomorrow. I don’t know if anyone else is on it, but I’ve noticed with Harvey, the past sort of 10 days, he’s wanting more portions, more snacks. So I think it needs to be upped, which they said every month.” She added that Harvey is scheduled for a weigh-in at his next clinic appointment: “He’s going to get weighed tomorrow, so you’ll find out next week how much he’s lost and they’ll be upping his dosage.”
Price also shared insights into the practical dietary management she has implemented: “Harvey has been on the Mounjaro nearly a month, he’s got one week left. I’ve been cooking meals like in the containers, batching cooking, then I’ve been eating them as well. I have noticed, I don’t know anyone else who has taken Mounjaro, a lot of my friends have, I asked them… The past week, Harvey is now wanting more food, more this, is that because he needs to up the level? Which they are doing in a week. I’ve noticed it. He goes back in a week and I can’t wait to see what he’s lost.”
Why This Matters
Harvey Price’s case highlights the complex clinical considerations when using GLP-1/GIP receptor agonists like tirzepatide in patients with rare genetic obesity syndromes such as Prader-Willi, particularly when polypharmacy and intellectual disability are present. The requirement for multi-disciplinary team approval underscores the safety protocols necessary when introducing these medications alongside existing treatments for seizure control, behavioral management, or hormonal replacement. The reported increase in appetite after several weeks on therapy aligns with known pharmacological phenomena where dose escalation is often required to maintain satiety effects as metabolic adaptation occurs. For families and clinicians managing similar complex cases, Price’s public documentation offers real-world insight into the challenges of balancing medication access, side effect monitoring, dietary support, and quality-of-life outcomes. The upcoming weigh-in and dosage adjustment will provide further data on Harvey’s individual response trajectory.
Frequently Asked Questions
What is Mounjaro and why was it chosen for Harvey Price?
Mounjaro (tirzepatide) is a dual GLP-1 and GIP receptor agonist injection approved for type 2 diabetes and, in some jurisdictions, for chronic weight management. It was chosen for Harvey Price after his medical team assessed his severe obesity—just under 30 stone with BMI double the obesity threshold—and determined the potential benefits for reducing cardiovascular risk and improving mobility outweighed the risks, despite his complex medication regimen for Prader-Willi syndrome, autism, and sight impairment.
How long has Harvey been on Mounjaro and what are the early results?
Harvey has been on Mounjaro for nearly one month as of Katie Price’s latest podcast update. While definitive weight loss figures are pending his scheduled clinic weigh-in, Price reports that over the past 10 days his appetite has increased, requesting more portions and snacks, which she and the clinical team interpret as a signal that his dosage requires the standard monthly escalation.
Is the treatment for cosmetic reasons?
No. Katie Price has explicitly stated: “This isn’t for looks, it’s for a better quality of life for him.” She cited Harvey’s breathlessness, inability to walk far, excessive sweating, and doctors’ warnings of high heart attack risk as the driving factors. Daily care challenges, such as bathing him twice daily due to his size, further underscore the medical necessity.
